Cargando…
Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
BACKGROUND: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF over-expr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012715/ https://www.ncbi.nlm.nih.gov/pubmed/24780003 http://dx.doi.org/10.1186/1423-0127-21-35 |
_version_ | 1782314961064689664 |
---|---|
author | Paudyal, Bishnuhari Paudyal, Pramila Shah, Dilip Tominaga, Hideyuki Tsushima, Yoshito Endo, Keigo |
author_facet | Paudyal, Bishnuhari Paudyal, Pramila Shah, Dilip Tominaga, Hideyuki Tsushima, Yoshito Endo, Keigo |
author_sort | Paudyal, Bishnuhari |
collection | PubMed |
description | BACKGROUND: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF over-expressing HT29 human colorectal cancer. Optical imaging was performed at 15 min, 24 h and 48 h post injection. Immunofluorescences staining of the tumor sections were performed. HT29 colorectal cancer xenografts were clearly visualized with bevacizumab-AlexaFluor 750. RESULTS: Ex vivo analysis showed 2.1 ± 0.4%, 37.6 ± 6.3% and 38.5 ± 6.2% injected dose/g accumulated in the tumors at 15 min, 24 h and 48 h respectively. Tumor uptake was significantly decreased in pretreated with excess of bevacizumab (p = 0.002). Immunofluorescence analysis showed strong staining of anti-CD 31 antibody around the blood vessels. Anti-VEGF-A and bevacizumab showed heterogeneous expression throughout the tumor. CONCLUSIONS: Current study successfully detected the VEGF expression in HT29 colorectal cancer xenografts, signifying as a potential agent for non-invasive imaging of VEGF expression, which may be applied in clinical practice. |
format | Online Article Text |
id | pubmed-4012715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40127152014-05-08 Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate Paudyal, Bishnuhari Paudyal, Pramila Shah, Dilip Tominaga, Hideyuki Tsushima, Yoshito Endo, Keigo J Biomed Sci Research BACKGROUND: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF over-expressing HT29 human colorectal cancer. Optical imaging was performed at 15 min, 24 h and 48 h post injection. Immunofluorescences staining of the tumor sections were performed. HT29 colorectal cancer xenografts were clearly visualized with bevacizumab-AlexaFluor 750. RESULTS: Ex vivo analysis showed 2.1 ± 0.4%, 37.6 ± 6.3% and 38.5 ± 6.2% injected dose/g accumulated in the tumors at 15 min, 24 h and 48 h respectively. Tumor uptake was significantly decreased in pretreated with excess of bevacizumab (p = 0.002). Immunofluorescence analysis showed strong staining of anti-CD 31 antibody around the blood vessels. Anti-VEGF-A and bevacizumab showed heterogeneous expression throughout the tumor. CONCLUSIONS: Current study successfully detected the VEGF expression in HT29 colorectal cancer xenografts, signifying as a potential agent for non-invasive imaging of VEGF expression, which may be applied in clinical practice. BioMed Central 2014-04-29 /pmc/articles/PMC4012715/ /pubmed/24780003 http://dx.doi.org/10.1186/1423-0127-21-35 Text en Copyright © 2014 Paudyal et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Paudyal, Bishnuhari Paudyal, Pramila Shah, Dilip Tominaga, Hideyuki Tsushima, Yoshito Endo, Keigo Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate |
title | Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate |
title_full | Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate |
title_fullStr | Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate |
title_full_unstemmed | Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate |
title_short | Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate |
title_sort | detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012715/ https://www.ncbi.nlm.nih.gov/pubmed/24780003 http://dx.doi.org/10.1186/1423-0127-21-35 |
work_keys_str_mv | AT paudyalbishnuhari detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate AT paudyalpramila detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate AT shahdilip detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate AT tominagahideyuki detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate AT tsushimayoshito detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate AT endokeigo detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate |